Best of the Week
Most Popular
1. Investing in a Bubble Mania Stock Market Trending Towards Financial Crisis 2.0 CRASH! - 9th Sep 21
2.Tech Stocks Bubble Valuations 2000 vs 2021 - 25th Sep 21
3.Stock Market FOMO Going into Crash Season - 8th Oct 21
4.Stock Market FOMO Hits September Brick Wall - Evergrande China's Lehman's Moment - 22nd Sep 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
7.AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
8.Why Silver Price Could Crash by 20%! - 5th Oct 21
9.Powell: Inflation Might Not Be Transitory, After All - 3rd Oct 21
10.Global Stock Markets Topped 60 Days Before the US Stocks Peaked - 23rd Sep 21
Last 7 days
Inflation Consequences for the Stock Market, FED Balance Sheet - 24th Oct 21
To Be or Not to Be: How the Evergrande Crisis Can Affect Gold Price - 24th Oct 21
During a Market Mania, "no prudent professional is perceived to add value" - 24th Oct 21
Stock Market S&P500 Rallies Above $4400 – May Attempt To Advance To $4750~$4800 - 24th Oct 21
Inflation and the Crazy Crypto Markets - 23rd Oct 21
Easy PC Upgrades with Motherboard Combos - Overclockers UK Unboxing - MB, Memory and Ryzen 5600x CPU - 23rd Oct 21
Gold Mining Stocks Q3 2021 - 23rd Oct 21
Gold calmly continues cobbling its Handle, Miners lay in wait - 23rd Oct 21
US Economy Has Been in an Economic Depression Since 2008 - 22nd Oct 21
Extreme Ratios Point to Gold and Silver Price Readjustments - 22nd Oct 21
Bitcoin $100K or Ethereum $10K—which happens first? - 22nd Oct 21
This Isn’t Sci-Fi: How AI Is About To Disrupt This $11 Trillion Industry - 22nd Oct 21
Ravencoin RVN About to EXPLODE to NEW HIGHS! Last Chance to Buy Before it goes to the MOON! - 21st Oct 21
Stock Market Animal Spirits Returning - 21st Oct 21
Inflation Advances, and So Does Gold — Except That It Doesn’t - 21st Oct 21
Why A.I. Is About To Trigger The Next Great Medical Breakthrough - 21st Oct 21
Gold Price Slowly Going Nowhere - 20th Oct 21
Shocking Numbers Show Government Crowding Out Real Economy - 20th Oct 21
Crude Oil Is in the Fast Lane, But Where Is It Going? - 20th Oct 21
3 Tech Stocks That Could Change The World - 20th Oct 21
Best AI Tech Stocks ETF and Investment Trusts - 19th Oct 21
Gold Mining Stocks: Will Investors Dump the Laggards? - 19th Oct 21
The Most Exciting Medical Breakthrough Of The Decade? - 19th Oct 21
Prices Rising as New Dangers Point to Hard Assets - 19th Oct 21
It’s not just Copper; GYX indicated cyclical the whole time - 19th Oct 21
Chinese Tech Stocks CCP Paranoia, VIES - Variable Interest Entities - 19th Oct 21
Inflation Peaked Again, Right? - 19th Oct 21
Gold Stocks Bouncing Hard - 19th Oct 21
Stock Market New Intermediate Bottom Forming? - 19th Oct 21
Beware, Gold Bulls — That’s the Beginning of the End - 18th Oct 21
Gold Price Flag Suggests A Big Rally May Start Soon - 18th Oct 21
Inflation Or Deflation – End Result Is Still Depression - 18th Oct 21
A.I. Breakthrough Could Disrupt the $11 Trillion Medical Sector - 18th Oct 21
US Economy and Stock Market Addicted to Deficit Spending - 17th Oct 21
The Gold Price And Inflation - 17th Oct 21
Went Long the Crude Oil? Beware of the Headwinds Ahead… - 17th Oct 21
Watch These Next-gen Cloud Computing Stocks - 17th Oct 21
Overclockers UK Custom Built PC 1 YEAR Use Review Verdict - Does it Still Work? - 16th Oct 21
Altonville Mine Tours Maze at Alton Towers Scarefest 2021 - 16th Oct 21
How to Protect Your Self From a Stock Market CRASH / Bear Market? - 14th Oct 21
The Only way to Crush Inflation (not stocks) - 14th Oct 21
Why "Losses Are the Norm" in the Stock Market - 14th Oct 21
Sub Species Castle Maze at Alton Towers Scarefest 2021 - 14th Oct 21
Which Wallet is Best for Storing NFTs? - 14th Oct 21
Ailing UK Pound Has Global Effects - 14th Oct 21
How to Get 6 Years Life Out of Your Overclocked PC System, Optimum GPU, CPU and MB Performance - 13th Oct 21
The Demand Shock of 2022 - 12th Oct 21
4 Reasons Why NFTs Could Be The Future - 12th Oct 21
Crimex Silver: Murder Most Foul - 12th Oct 21
Bitcoin Rockets In Preparation For Liftoff To $100,000 - 12th Oct 21
INTEL Tech Stock to the MOON! INTC 2000 vs 2021 Market Bubble WARNING - 11th Oct 21
AI Stocks Portfolio Buying and Selling Levels Going Into Market Correction - 11th Oct 21
Stock Market Wall of Worry Meets NFPs - 11th Oct 21
Stock Market Intermediate Correction Continues - 11th Oct 21
China / US Stock Markets Divergence - 10th Oct 21
Can US Save Taiwan From China? Taiwan Strait Naval Battle - PLA vs 7th Fleet War Game Simulation - 10th Oct 21
Gold Price Outlook: The Inflation Chasm Between Europe and the US - 10th Oct 21
US Real Estate ETFs React To Rising Housing Market Mortgage Interest Rates - 10th Oct 21
US China War over Taiwan Simulation 2021, Invasion Forecast - Who Will Win? - 9th Oct 21
When Will the Fed Taper? - 9th Oct 21
Dancing with Ghouls and Ghosts at Alton Towers Scarefest 2021 - 9th Oct 21
Stock Market FOMO Going into Crash Season - 8th Oct 21
Scan Computers - Custom Build PC 6 Months Later, Reliability, Issues, Quality of Tech Support Review - 8th Oct 21
Gold and Silver: Your Financial Main Battle Tanks - 8th Oct 21
How to handle the “Twin Crises” Evergrande and Debt Ceiling Threatening Stocks - 8th Oct 21
Why a Peak in US Home Prices May Be Approaching - 8th Oct 21
Alton Towers Scarefest is BACK! Post Pandemic Frights Begin, What it's Like to Enter Scarefest 2021 - 8th Oct 21
AJ Bell vs II Interactive Investor - Which Platform is Best for Buying US FAANG Stocks UK Investing - 7th Oct 21
Gold: Evergrande Investors' Savior - 7th Oct 21
Here's What Really Sets Interest Rates (Not Central Banks) - 7th Oct 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

5 Biotech Stocks That You Should Be Watching Right Now!

Companies / BioTech Apr 08, 2019 - 02:03 PM GMT

By: Submissions


The world of biotechnology is changing rapidly. Today, there are more answers for medical questions than ever before. However, that doesn’t mean that innovation is coming to an end. Several companies dedicate their efforts to finding solutions for some of the world’s most debilitating conditions.

This medical innovation has led to droves of investor interest. As more and more companies find solutions, more and more investors are finding profits. However, as with any investment, investing in the biotechnology space can come with risk.

With many of these companies being in clinical stages, they are highly dependent on investor interest, clinical success, and the news that they release. Positive news can drive these stocks up dramatically while negative news will generally lead to large declines. Today, we’ll talk about the 5 biotech stocks that are consistently sharing positive news, making them some of the most interesting investment opportunities on the market today.

#1: AbbVie (NYSE: ABBV)

In my opinion, AbbVie is a highly undervalued biotech stock that presents an opportunity that’s hard to ignore. You may think that at a market cap of over $122 billion, it’s hard to find anything undervalued. However, in this case, the term undervaluation is far more than warranted.

AbbVie’s claim to fame is Humira. Humira is a prescription drug that was developed to address pain and inflammation problems that come as the result of autoimmune disorders. Some of these autoimmune disorders include rheumatoid arthritis, plaque psoriasis, and Crohn’s disease.
Here are the key reasons that I believe investors should be paying attention to AbbVie:

  1. Top-Line Growth - Over the past three years, AbbVie has generated compelling growth in revenue. In fact, the company has seen top-line growth in the amount of 12.4% through this period. At the moment, the industry average top-line growth comes in at approximately 5.8%. With top-line growth of 12.4%, AbbVie outranks 72% of its competitors.
  2. EBITDA Growth - As if top-line growth wasn’t enough to excite, it’s worth taking a look at the company’s EBITDA growth. This figure comes in at about 43%. At this rate, the company ranks among the top ten biotech stocks on the market today.
  3. Humira Sales - Finally, the company’s flagship product isn’t showing any signs of slowing sales.  Humira sales grew from just $7.9 billion in 2011 to nearly $20 billion in 2018. In fact, sales have climbed by more than 8% in the last year, and based on trends since the drug was approved, sales will likely continue in the right direction.

#2: Cellectar Biosciences (NASDAQ: CLRB)

Cellectar Biosciences is another contender in the biotech space that is well worth paying attention to. In most cases, I would stay away from clinical-stage biotech companies as they tend to be highly speculative investments. However, in the case of Cellectar Bioscience, an extreme undervaluation coupled with strong clinical data suggests that the stock may see strong gains ahead.

Cellectar’s claim to fame is a lineup of what they call phospholipid drug conjugates (PDCs). These PDCs allow the company to target cancer cells with laser-like precision. Through their targeted delivery method, data suggests that the company is capable of treating cancerous tumors with radiation that will lead to few or no serious adverse events.

Moreover, the highly-targeted nature of the company’s proprietary PDCs, allows it to use less radiation while achieving the same or better results. This ultimately leads to fewer doses needing to be endured by the patient and an improved quality of life.
Key reasons to pay attention to Cellectar Biosciences:

  1. As mentioned above, Cellectar Biosciences’ proprietary PDC delivery method is a very unique value proposition. Because of the extreme targeting that this delivery method provides, patients are able to undergo less frequent treatment. Moreover, the finely tuned targeting of the company’s PDC platform allows for the avoidance of surrounding tissue, leading to a low risk of serious adverse events (SAEs).
  2. Another factor worth mentioning here is that the company is not looking to take down the easiest targets. Instead, they have based their clinical trials around cancer patients that have seen multiple lines of previous therapy. With each line of therapy, potential for efficacy drops dramatically. However, in a recent clinical study, the company addressed patients who have received at least 5 prior lines of therapy. While this was a risky move, it paid off. In fact, the company’s CLR-131 candidate, one which uses its proprietary PDC delivery method, showed that even in this difficult-to-treat population, it was able to extend overall survival by 22 months. This level of success in heavily pre-treated patients is hard to come by, further expanding the value proposition offered by Cellectar Biosciences.
  3. Finally, there are several market-moving catalysts ahead. In fact, the company has 7 planned clinical data readouts in 2019. Should the data ahead be as positive as the data that we’ve seen in the past, we can expect these readouts to lead to impressive gains. However, Cellectar Biosciences is a company that is consistently sending out news. So, the potential for interim analysis announcements, peer reviewed publications, and other updates between these 7 data readouts is very high. Each announcement or piece of news has the potential to lead to positive movement.

#3: Sarepta Therapeutics (NASDAQ: SRPT)

Next, we have Sarepta Therapeutics. The company’s claim to fame is EXONDYS 51, the first and only FDA approved treatment indicated for Duchenne Muscular Dystrophy, also commonly known as DMD.

DMD is a rare pediatric disease that affects about one in every 3,600 male infants. Unfortunately, the condition is one that leads to a reduced quality of life and shorter lifespan. In fact, patients with DMD usually pass in their 20s and 30s.

With the only approved treatment on the market, Sarepta Therapeutics enjoys a monopoly. Moreover, generic competition is far off due to the strong IP protection that the company has amassed over the years.

Here are a few reasons why Sarepta Therapeutics should be on your watch list:

  1. One of the biggest reasons to keep an eye on Sarepta Therapeutics is EXONDYS 51 sales growth. In fact, in the fourth quarter of 2018, the company generated sales in the amount of $84.4 million. While some were upset with the fact that the figure was slightly below analyst expectations of $86 million, the truth of the matter is that the $84.4 million generated represents a year-over-year growth rate of more than 47%.
  2. It’s also worth mentioning that Sarepta Therapeutics has a large pipeline with several candidates in late stages of development. In fact, at the moment, there are currently 9 clinical assets under development, 10 pre-clinical development programs, and 5 programs currently in research and development. With such a robust, pipeline there are several potential catalysts ahead.
  3. Finally, some of the most valuable medications in the world are those that address rare, life-threatening diseases. With the approval of EXONDYS 51, the company has proven its ability to target these types of diseases and will likely continue to do so in the future. This greatly adds to the value proposition offered.

#4: Aerie Pharmaceuticals (NASDAQ: AERI)

Another biotech stock that’s well worth keeping an eye on is Aerie Pharmaceuticals. The company recently achieved its first FDA approval and may have another knocking on the door.

The first approval was for Rhopressa, a treatment developed to relieve intraocular pressure caused by open angular glaucoma and ocular hypertension. While the treatment was just launched last year, the company is already seeing meaningful sales. In fact, in the third quarter of 2018 alone, Aerie Pharmaceuticals reported more than $7 million in revenue generated through the sale of Rhopressa. The second approval was announced in March, when the FDA approved Rocklatan, yet another treatment designed for glaucoma.

Key reasons to watch Aerie Pharmaceuticals:

  1. First and foremost, while Aerie Pharmaceuticals has done a great job to date with the commercialization of Rhopressa, sales are likely to climb in an even more meaningful way. Being only a month away from the approval of Rocklatan, the company now has an opportunity to expand revenue with the launch of this treatment.
  2. Another reason that Aerie Pharmaceuticals is so interesting is the space in which it works. At the moment, the company is targeting the intraocular pressure and glaucoma markets. With little competition in the space, the company could quickly become a cornerstone in the treatment of these conditions.
  3. Finally, Aerie Pharmaceuticals is another company with a seriously impressive pipeline. With two approved treatments under its belt, it’s hard to argue against the company’s ability to bring a treatment to market. This, combined with a pipeline consisting of six clinical development programs, opens the door to impressive potential ahead.

#5 bluebird bio (NASDAQ: BLUE)
Finally, we have bluebird bio. Bluebird bio is a clinical-stage biotechnology company that’s on the verge of a break into the commercial space, and has strong partnerships to help it through the process.

For bluebird bio, the claim to fame is its LentiGlobin gene therapy. The therapy was designed to reduce the need for blood transfusions in patients with beta-thalassemia, and if approved, it could be a game changer in the treatment of this condition.
Key reasons to keep an eye on bluebird bio:

  1. First and foremost, bluebird bio is on the verge of breaking into the commercial phase. Currently, the company has an application waiting for approval in Europe. In fact, it is expected that the EMA will make its decision on LentiGlobin later this year. The company also plans to file a New Drug Application with the United States FDA relatively soon. Approvals in either of these regions could lead to substantial gains in the value of the stock.
  2. It’s also worth mentioning that the target audience for LentiGlobin is a massive one. It is estimated that about 60,000 people are born with beta thalassemia around the world each year. 1,500 of these patients are born in the United States. With a treatment like nothing else on the market, the company’s LentiGlobin product could be a go-to option for this large patient population.
  3. Finally, bluebird bio has an impressive pipeline that’s worth looking at. Currently, there are 3 assets in late stage development and five assets in the early stages of development. With a robust pipeline like this, there are several potential catalysts ahead.

Final Thoughts
The biotechnology space is one that is filled with opportunity. However, there are a few companies that I believe stand above the rest when it comes to potential for growth. I believe that the companies listed above fit that bill. If you haven’t already started to look into them, now is the time!

By Joshua Rodriguez

© 2019 Copyright Joshua Rodriguez - All Rights Reserved

Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.

© 2005-2019 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in